Eosinophilic Esophagitis Pipeline Insight
DelveInsight’s, “Eosinophilic Esophagitis – Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Eosinophilic Esophagitis Understanding
Eosinophilic Esophagitis: Overview
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated/allergen-mediated clinicopathological condition. It is characterised clinically by symptoms of oesophageal dysfunction (e.g., dysphagia and food impaction in adolescents and adults, and vomiting, regurgitation, heartburn, abdominal pain, failure to thrive, or feeding intolerance in children), and histologically by an eosinophilic infiltration of the oesophageal epithelium of ≥15 eosinophils per high-power microscopy field in the absence of other causes of local or systemic eosinophilia. Normally there are no eosinophils in the esophagus. A person with EoE will have inflammation and increased numbers of eosinophils in the esophagus. The chronic inflammation of EoE leads to symptoms. Early diagnosis and treatment of EoE is important to prevent progression to fibrotic changes in the esophagus which may be only partially reversible. Currently, performing an upper endoscopy with biopsies of the esophagus is necessary to diagnose EoE. Current management of EoE includes food elimination diets, off label use of proton pump inhibitors, and glucocorticoid steroid formulations.
"Eosinophilic Esophagitis - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eosinophilic Esophagitis pipeline landscape is provided which includes the disease overview and Eosinophilic Esophagitis treatment guidelines. The assessment part of the report embraces, in depth Eosinophilic Esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eosinophilic Esophagitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Eosinophilic Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve Eosinophilic Esophagitis.
Eosinophilic Esophagitis Emerging Drugs Chapters
This segment of the Eosinophilic Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Eosinophilic Esophagitis Emerging Drugs
TAK-721 (budesonide oral suspension) is a novel mucoadherent topically active oral viscous formulation of budesonide, formulated specifically as an investigational treatment for eosinophilic esophagitis (EoE). The suspension is intended to treat the localized esophageal inflammation that is caused by EoE. The TAK-721 development program is the first and largest EoE Phase 3 clinical trial program in the U.S. to report results. The NDA filing is based on data from the pivotal Phase 3 trials ORBIT1 and ORBIT2, which investigated the safety and efficacy of TAK-721 in adolescent and adult patients (11 to 55 years of age) with EoE. U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis. TAK-721 previously received both Breakthrough Therapy designation and Orphan Drug designation from the FDA.
APT-1011: Ellodi Pharma
APT-1011 is a novel, proprietary, oral disintegrating tablet delivering fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 was shown to be effective in reducing esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. It is currently in Phase 3 development (FLUTE II), following successful completion of its Phase 2 study (FLUTE I) in 2019. APT-1011 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Further product details are provided in the report……..
Eosinophilic Esophagitis: Therapeutic Assessment
This segment of the report provides insights about the different Eosinophilic Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Eosinophilic Esophagitis
There are approx. 15+ key companies which are developing the therapies for Eosinophilic Esophagitis. The companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Preregistration include, Takeda.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Eosinophilic Esophagitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Eosinophilic Esophagitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Eosinophilic Esophagitis drugs.
Eosinophilic Esophagitis Report Insights
- Eosinophilic Esophagitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Eosinophilic Esophagitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Eosinophilic Esophagitis drugs?
- How many Eosinophilic Esophagitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Eosinophilic Esophagitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Esophagitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Eosinophilic Esophagitis and their status?
- What are the key designations that have been granted to the emerging drugs?